A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 28 Jul 2025
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms MIGHTY
- Sponsors AbbVie
Most Recent Events
- 28 Jul 2025 New trial record